IL4 and Pruritus: Additionally, delgocitinib inhibits IL-31-induced pruritus, contributing to symptom relief [13]. In this case, dupilumab administration effectively suppressed the inflammatory cytokines involved in pruritus (IL-4 and IL-13), resulting in well-controlled trunk lesions.